CD38 inhibitors and methods of treatment
Compounds of Formula I and methods of treating diseases of metabolism by modulating cellular NAD+ levels through the inhibition of the CD38 enzyme, are disclosed.
1. A compound of Formula I
wherein Q is O, NH, N(H)C(O), or C(O)N(H);
R 1 is C 1-5 alkylS(O) 2 CH 3 , or C 1-6 alkyl wherein said alkyl can comprise straight-chain portions, branched chain portions, cycloalkyl portions, and wherein said C 1-6 alkyl is optionally substituted by one OH or OCH 3 and wherein said C 1-6 alkyl is optionally further substituted by 1 to 3 Fluorine atoms; and
R 2 is H, C 1-3 alkyl, or halogen.
2. A pharmaceutically acceptable salt of a compound of Formula I
wherein Q is O, NH, N(H)C(O), or C(O)N(H);
R 1 is C 1-5 alkylS(O) 2 CH 3 , or C 1-6 alkyl wherein said alkyl can comprise straight-chain portions, branched chain portions, cycloalkyl portions, and wherein said C 1-6 alkyl is optionally substituted by one OH or OCH 3 and wherein said C 1-6 alkyl is optionally further substituted by 1 to 3 Fluorine atoms; and
R 2 is H, C 1-3 alkyl, or halogen.
3. A compound according to claim 1 wherein R 2 is H or Cl.
4. A compound according to claim 1 wherein R 2 is H.
5. A compound according to claim 1 wherein the orientation on the cyclohexyl ring is trans as depicted below
6. The compound